Reckitt Benckiser Group/£RKT

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About Reckitt Benckiser Group

Reckitt Benckiser Group is a British multinational consumer goods company headquartered in Slough, England. It operates within the health, hygiene, and home product categories. The company's key brands include Dettol, Lysol, Durex, and Nurofen, offering a wide range of products from disinfectants to pharmaceuticals. Founded in 1999 through the merger of Reckitt & Colman and Benckiser, the company has a significant global presence, with operations in over 60 countries. Reckitt Benckiser's strategic strength lies in its diversified product portfolio and strong brand recognition, which facilitate its competitive positioning in various consumer markets.

Ticker

£RKT

Primary listing

LSE

Employees

37,900

RKT Metrics

BasicAdvanced
£39B
32.06
£1.80
0.07
£1.22
2.11%

What the Analysts think about RKT

Analyst ratings (Buy, Hold, Sell) for Reckitt Benckiser Group stock.

Bulls say / Bears say

Reckitt's main brands—Lysol, Dettol, and Strepsils—achieved 5.3% revenue growth in Q2, topping the forecasted 3.4%, which drove shares 9% higher and led to an upgrade of full-year core like-for-like net revenue guidance above 4%, overcoming currency challenges. (WSJ)
The company is leveraging strong growth in emerging markets, maintaining double-digit sales growth in China, and investing 300 million yuan ($40.9 million) in a new Shanghai R&D center to support local innovation. (Bloomberg)
Reckitt has launched a £1 billion share buyback and increased its interim dividend by 5% to 84.4 pence, reflecting robust free cash flow and reaffirming its commitment to returning value to shareholders. (MarketScreener)
Group net revenue for Q2 decreased 3.8% to £3.3 billion year-on-year, indicating overall sales are under pressure despite strong performance from core brands. (WSJ)
In Q4, Reckitt's Health segment delivered only 2.4% growth compared to the anticipated 6.9%, as a mild cold and flu season negatively impacted over-the-counter medicine sales. (Reuters)
Reckitt remains exposed to valuation risks on its Essential Home divestment, having received bids below expectations. This underperforming unit saw a 7% like-for-like sales drop in Q1, leading the company to consider alternative structuring for the deal. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.

RKT Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RKT Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £RKT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

Sept18
Reckitt Benckiser Group
DividendPayment
£0.844Per share
FAQs